Key Insights

Highlights

Treatment Research

2 treatments under study, led by Exv801

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07284472Phase 2/3Recruiting

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Showing all 1 trials

Research Network

Common Treatments

  • Exv8011
  • Exv8021

Active Sponsors

  • Exciva GmbH1

Related Conditions

  • Agitation Associated With Alzheimers Disease Dementia1

Activity Timeline